Pharmacielo Ltd (PCLO)

PharmaCielo Announces the Issuance of Interest Shares and Update on Insider Bridge FinancingMay 19, 2026 7:30 AM
NewsfileAll figures in Canadian dollars ($) unless otherwise specifiedToronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - May 19, 2026) - PharmaCielo Ltd. (TSXV: PCLO) (OTC Pink: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced that, as approved by the TSX Venture Exchange (the "TSXV"), it has issued 11,145,999 common shares of PharmaCielo ("Interest Shares"), at an effective price of $0.08 per Interest Share, in satisfaction of an aggregate of $891,681.85 of semi-annual interest payable to holders of the Company's 11% secured debentures (the "Debentures") (the "Shares for Debt Transaction"). The effective price of the Interest Shares was determined by dividing the cash interest otherwise payable by the number of shares issuable under each Debenture, in accordance with the terms of the Debentures and TSXV Policy 4.3, section 3.3. The Interest Shares are subject to the balance, if any, of the 4-month statutory hold period.The issuance of Interest Shares to L5 Capital Inc., Marc Lustig, William Petron and Ian Atacan constitutes a "related party transaction" within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is relying on exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 pursuant to sections 5.5(a) and 5.7(1)(a) of MI 61-101, as the fair market value of the transaction does not exceed 25% of the Company's market capitalization.Insider Bridge FinancingSince February 2024, the Company's working capital requirements have been supported primarily through a secured insider bridge loan facility provided by Marc Lustig and certain insiders of the Company, bearing interest at 11% per annum. To date, PharmaCielo has drawn approximately $2.5 million of the $3.0 million commitment.The Company believes this continued financial support reflects insider confidence in PharmaCielo's long term strategy and ongoing operations. The bridge financing has assisted the Company in maintaining operations while continuing to focus on cost reductions, operational efficiencies, and commercial development initiatives. About PharmaCieloPharmaCielo Ltd. (TSXV: PCLO) (OTC Pink: PCLOF) is a global company, headquartered in Canada, with a focus on ethical and sustainable cultivating, processing and supply of all natural, pharmaceutical-grade medicinal and commercial dried cannabis flower and cannabis products to large channel distributors. PharmaCielo's principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its cultivation and processing center located in Rionegro, Colombia.For further informationIan Atacan, Chief Financial Officer
i.atacan@pharmacielo.com Media and Investor Inquiries:
investors@pharmacielo.com Forward-Looking StatementsThis news release contains forward-looking statements. Forward-looking statements can be identified by the use of words such as "expects", "is expected", "intends", "anticipates", "believes", or variations of such words and phrases or state that certain actions, events or results "may" or "will" be taken, occur or be completed or achieved. Forward-looking statements can be affected by known and unknown risks, uncertainties and other factors, including changes to PharmaCielo's development plans, the failure to obtain and maintain all necessary regulatory approvals relating to the export of cannabinoid products and the import of these products into other countries, TSX Venture Exchange approval, the inability to export or distribute commercial products through sales channels as anticipated due to economic or operational circumstances, risks associated with operating in Colombia, fluctuation of the market price for the Company's products, risks associated with global economic and political instability or other developments, risks related to retention of key Company personnel, currency exchange risk, competition in PharmaCielo's market and other risks discussed or referred to under the heading "Risk Factors" in PharmaCielo's Annual Information Form for the financial year ended December 31, 2019, which is available at www.sedar.com. Accordingly, readers should not place undue reliance on forward-looking statements. Except as required by law, PharmaCielo undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297650 Original: PharmaCielo Announces the Issuance of Interest Shares and Update on Insider Bridge Financing

PharmaCielo Announces Intention to Issue Interest SharesApril 17, 2026 7:30 AM
NewsfileAll figures in Canadian dollars ($) unless otherwise specifiedToronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - April 17, 2026) - PharmaCielo Ltd. (TSXV: PCLO) (OTC Pink: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and food and medicinal grade cannabis extracts for the natural pharmaceuticals and consumer products market, PharmaCielo Colombia Holdings S.A.S., today announced that it intends to issue, subject to the approval of the TSX Venture Exchange, 11,145,999 common shares of PharmaCielo ("Interest Shares"), at an effective price of $0.08 per Interest Share, in satisfaction of an aggregate of $891,681.85 in accrued semi annual interest payments due to holders of the Company's 11% secured debentures (the "Debentures").The effective price of the Interest Shares was determined by dividing the cash interest otherwise payable by the number of shares issuable under each Debenture, in accordance with the terms of the Debentures and TSX Venture Exchange Policy 4.3, section 3.3. The Interest Shares are subject to the balance, if any, of the applicable statutory hold period under Canadian securities laws. About PharmaCieloPharmaCielo Ltd. (TSXV: PCLO) (OTC Pink: PCLOF) is a global company, headquartered in Canada, with a focus on ethical and sustainable cultivating, processing and supply of all natural, pharmaceutical-grade medical dried cannabis flower and cannabis extracts for the natural pharmaceuticals and consumer products market. PharmaCielo's principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its cultivation and processing center located in Rionegro, Colombia.For further informationIan Atacan, Chief Financial Officer
i.atacan@pharmacielo.com Media and Investor Inquires:
investors@pharmacielo.com Forward-Looking StatementsThis news release contains forward-looking statements. Forward-looking statements can be identified by the use of words such as "expects", "is expected", "intends", "anticipates", "believes", or variations of such words and phrases or state that certain actions, events or results "may" or "will" be taken, occur or be completed or achieved. Forward-looking statements in this news release include, without limitation, statements regarding potential financing transactions, and the possible conversion of debentures.The forward-looking statements in this news release are necessarily based on assumptions, including assumptions with respect to PharmaCielo's ability to obtain necessary approvals for the issuance of the interest shares.Forward-looking statements can be affected by known and unknown risks, uncertainties and other factors, including changes to PharmaCielo's development plans, the failure to obtain and maintain all necessary regulatory approvals relating to the export of cannabinoid products and the import of these products into other countries, TSX Venture Exchange approval, the inability to export or distribute commercial products through sales channels as anticipated due to economic or operational circumstances, risks associated with operating in Colombia, fluctuation of the market price for the Company's products, risks associated with global economic and political instability or other developments, risks related to retention of key Company personnel, currency exchange risk, competition in PharmaCielo's market and other risks discussed or referred to under the heading "Risk Factors" in PharmaCielo's Annual Information Form for the financial year ended December 31, 2019, which is available at www.sedar.com. Accordingly, readers should not place undue reliance on forward-looking statements. Except as required by law, PharmaCielo undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/292896
Original: PharmaCielo Announces Intention to Issue Interest Shares

PharmaCielo Announces the Issuance of Interest SharesMarch 17, 2026 7:30 AM
NewsfileAll figures in Canadian dollars ($) unless otherwise specifiedToronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - March 17, 2026) - PharmaCielo Ltd. (TSXV: PCLO) (OTC Pink: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced that, as approved by the TSX Venture Exchange (the "TSXV"), it is issuing 12,153,937 common shares of PharmaCielo ("Interest Shares"), at an effective price of $0.08 per Interest Share, in satisfaction of an aggregate of $972,317.12 of semi-annual interest payable to holders of the Company's 11% secured debentures (the "Debentures") (the "Shares for Debt Transaction"). The effective price of the Interest Shares was determined by dividing the cash interest otherwise payable by the number of shares issuable under each Debenture, in accordance with the terms of the Debentures and TSXV Policy 4.3, section 3.3. The Interest Shares are subject to the balance, if any, of the 4-month statutory hold period.The issuance of Interest Shares to L5 Capital Inc., Marc Lustig, William Petron and Ian Atacan constitutes a "related party transaction" within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is relying on exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 pursuant to sections 5.5(a) and 5.7(1)(a) of MI 61-101, as the fair market value of the transaction does not exceed 25% of the Company's market capitalization.Annual General and Special Meeting
The Company's next Annual General Meeting ("AGM") will be held on April 2, 2026, at 11:00 a.m. Eastern Time at 82 Richmond Street East, Toronto, Ontario, M5C 1P1. Shareholders will be asked to elect directors, appoint auditors, and consider other customary business. Shareholders may also participate in the meeting online or by dialing in at the below dial-in number approximately 5 to 10 minutes prior to the scheduled start time.Date and Time:Thursday, April 2, 2026, at 11:00 a.m. (Toronto time)On-line Meeting Link: https://zoom.us/j/96949238343Dial-in Numbers: +1 689 278 1000,,96949238343# +1 719 359 4580,,96949238343# from Canada or the USMeeting ID: 969 4923 8343Passcode: 527692# About PharmaCieloPharmaCielo Ltd. (TSXV: PCLO) (OTC Pink: PCLOF) is a global company, headquartered in Canada, with a focus on ethical and sustainable cultivating, processing and supply of all natural, pharmaceutical-grade medicinal and commercial dried cannabis flower and cannabis products to large channel distributors. PharmaCielo's principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its cultivation and processing center located in Rionegro, Colombia.For further informationIan Atacan, Chief Financial Officer
i.atacan@pharmacielo.com Media and Investor Inquiries:
investors@pharmacielo.com Forward-Looking StatementsThis news release contains forward-looking statements. Forward-looking statements can be identified by the use of words such as "expects", "is expected", "intends", "anticipates", "believes", or variations of such words and phrases or state that certain actions, events or results "may" or "will" be taken, occur or be completed or achieved. Forward-looking statements can be affected by known and unknown risks, uncertainties and other factors, including changes to PharmaCielo's development plans, the failure to obtain and maintain all necessary regulatory approvals relating to the export of cannabinoid products and the import of these products into other countries, TSX Venture Exchange approval, the inability to export or distribute commercial products through sales channels as anticipated due to economic or operational circumstances, risks associated with operating in Colombia, fluctuation of the market price for the Company's products, risks associated with global economic and political instability or other developments, risks related to retention of key Company personnel, currency exchange risk, competition in PharmaCielo's market and other risks discussed or referred to under the heading "Risk Factors" in PharmaCielo's Annual Information Form for the financial year ended December 31, 2019, which is available at www.sedarplus.ca. Accordingly, readers should not place undue reliance on forward-looking statements. Except as required by law, PharmaCielo undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/288764
Original: PharmaCielo Announces the Issuance of Interest Shares

PharmaCielo Announces 2025 Q3 Results, AGM DetailsMarch 2, 2026 7:30 AM
NewsfileAchieves Positive Adjusted EBITDAAll figures in Canadian dollars ($) unless otherwise specifiedToronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - March 2, 2026) - PharmaCielo Ltd. (TSXV: PCLO) (OTC Pink: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced results of the quarter ended December 31, 2025.Summary Financials - Third Quarter Ended December 31, 2025
Nine months ended(000's)December 31, 2025December 31, 2024Revenue $ 1,818$ 3,240Adjusted EBITDA* (Loss)$ 293$ (2,295)Net Loss$ (2,279)$ (6,721)Net Loss per Share$ (0.01)$ (0.04) *Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization). The term Adjusted EBITDA does not have any standardized meaning under IFRS Accounting Standards. Therefore, it may not be comparable to similar measures presented by other companies.For further detailed information and analysis, please see the financial statements and management's discussion and analysis for the period ending December 31, 2025, as posted at sedarplus.ca and pharmacielo.com.Management Commentary
Marc Lustig, Chairman and CEO of PharmaCielo, commented, "The third quarter marked an important turning point for PharmaCielo. We have re-established a solid foundation from which to rebuild momentum and create long-term shareholder value. The revenue for the nine-month period reflects a deliberate transition in our commercial strategy. The significant improvement in Adjusted EBITDA demonstrates the operational discipline and cost controls implemented over the past year. Our focus has been on rightsizing the organization, improving production efficiencies in Colombia, and prioritizing higher margin export opportunities. Our near-term objectives are clear: drive consistent export volumes, strengthen our relationships with strategic international partners, and secure repeat purchase agreements that support predictable revenue growth."Annual General and Special Meeting
The Company's most recent Annual General Meeting ("AGM") was held on February 20, 2024. The upcoming AGM will be held on April 2, 2026, at 11:00 a.m. Eastern Time at 82 Richmond Street East, Toronto, Ontario, M5C 1P1. The record date for determining shareholders entitled to vote at the AGM was set as February 23, 2026. Shareholders will be asked to elect directors, appoint auditors, and consider other customary business.About PharmaCieloPharmaCielo Ltd. (TSXV: PCLO) (OTC Pink: PCLOF) is a global company, headquartered in Canada, with a focus on ethical and sustainable cultivating, processing and supply of all natural, pharmaceutical-grade medicinal and commercial dried cannabis flower and cannabis products to large channel distributors. PharmaCielo's principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its cultivation and processing center located in Rionegro, Colombia.For further informationIan Atacan, Chief Financial Officer
i.atacan@pharmacielo.com Media and Investor Inquires:
investors@pharmacielo.com Forward-Looking StatementsThis news release contains forward-looking statements. Forward-looking statements can be identified by the use of words such as "expects", "is expected", "intends", "anticipates", "believes", or variations of such words and phrases or state that certain actions, events or results "may" or "will" be taken, occur or be completed or achieved. Forward-looking statements in this news release include, without limitation, statements regarding potential financing transactions, and the possible conversion of debentures.The forward-looking statements in this news release are necessarily based on assumptions, including assumptions with respect to PharmaCielo's ability to obtain necessary approvals for the issuance of the debenture units.Forward-looking statements can be affected by known and unknown risks, uncertainties and other factors, including changes to PharmaCielo's development plans, the failure to obtain and maintain all necessary regulatory approvals relating to the export of cannabinoid products and the import of these products into other countries, TSX Venture Exchange approval, the inability to export or distribute commercial products through sales channels as anticipated due to economic or operational circumstances, risks associated with operating in Colombia, fluctuation of the market price for the Company's products, risks associated with global economic and political instability or other developments, risks related to retention of key Company personnel, currency exchange risk, competition in PharmaCielo's market and other risks discussed or referred to under the heading "Risk Factors" in PharmaCielo's Annual Information Form for the financial year ended December 31, 2019, which is available at www.sedarplus.ca. Accordingly, readers should not place undue reliance on forward-looking statements. Except as required by law, PharmaCielo undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285827
Original: PharmaCielo Announces 2025 Q3 Results, AGM Details

NLST get some ... your DD for the day! Buy buy buy! Partnership news!

MAN what a screw up this industry's been.....



12 months later.....



Sure dodged a bullet there.......

Bbrrf paid 1 million 500 thousand for 12 acres in columbia. And they had the same ceo that used to be at pharm. Of course he split bbrrf months ago. Had no ideal property in a 3rd world country that is in the country and void of buildings is so expensive.

Let's start a weed buisness in south america and sell shares to sucker americans. Notice they dont bother with Europe.

Let's start a weed buisness in south america and sell shares to sucker americans. Notice they dont bother with Europe.

Hindenburg Research
@HindenburgRes

PharmaCielo's response this morning is wholly inadequate and addresses none of the issues we raised, nor does it offer any refutation of the specifics of our report. $PCLO $PCLOF's press release simply declares everything in our report to be false.

We pointed out that a CURRENT director (and original co-founder) misrepresented a bankruptcy & engaged in what appears to be brazen self-enrichment scheme with $PCLO $PCLOF's CURRENT largest shareholder. The company simply re-iterates its bull thesis (which we also debunked).

Shareholders would have been better served by $PCLO $PCLOF commenting on the Cauca greenhouse that doesn't exist, the fact that partner General Extract belongs to a former $PCLO COO, partner XPhyto's CEO's history of failed companies, or plans to deal with cash burn.

As far as $PCLO $PCLOF's vague legal threat at the end of its response, we would encourage the company to publicly detail any and all facts and/or specifics rebutting our research. But we think the public will be waiting a long time for that response, too.

PharmaCielo: 100% Downside on Co-Founder’s History of Securities Fraud Allegations, Numerous Undisclosed Related Party Transactions and Operational

New report just out https://hindenburgresearch.com/pharmacielo/

I don’t think the woes of the “weed industry” have anything to do with PCLO’s struggle; there is absolutely no benefit to producing CBD in greenhouses, in Colombia... Colombian taxes and then tariffs make doing so a moot point when you look at the economics of growing hemp in the good ole USA. PCLO was a scam we called out when we went to Colombia to evaluate the viability of CBD production there last March. The bottom will fall out of the PCLO house of cards soon enough.

Time for investors to admit the weed industry is not what thought it would be. Even shill Cramer just came out and said he was wrong about being positive on this sector. States who had medical weed for years such as michigan should have been the crystal ball. Anyone could get a medical cars for $4o,or anyone over 21. The weed shops that opened on every corner after medical legalization are closed! 95% of them. That is the future for recreational weed. Pot stocks will drop another 50% across the board.

Yes the intrinsic cost of producing most of the weed products to be consumed are much higher in USA than the black market stuff and this will BK most growers who already cannot put money in federal banks, nor get a mortgage to get loans on their properties. They need expensive permits (confiscatory bleedings) for almost everything and must measure and account for every last atom of the plant's cycle.
I have been involved with buying some of the best properties, in a group and renting it back to the proprietors, but that is not a no brainer,......... ok it gives them a cash infusion , buy how long can they hold on and pay rent ?

All strive to have a highly regarded "branded" product but they need vast channels of advertising and those channels are currently forbidden, except for the marginal social media fads.

How is the landscape in Canada for this fledging industry?

TORONTO, Nov. 5, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF) announces that earlier today it was advised by Creso Pharma Limited ("Creso Pharma") that due to BDO Corporate Finance (WA) Pty Ltd. changing its independent expert report to conclude that the PharmaCielo Share Scheme is neither fair nor reasonable and is not in the best interests of shareholders of Creso Pharma, it is impossible for the Board of Directors of Creso Pharma to support the Share and Option Schemes (the "Schemes") in their current form. As a result of the Creso Pharma Board of Directors changing its recommendation in respect of the Schemes, PharmaCielo has terminated the Scheme Implementation Agreement (the "Scheme Implementation Agreement"), originally announced on June 6, 2019, in accordance with its terms. No break or expense reimbursement fees are payable by either PharmaCielo or Creso Pharma in connection with the termination of the Scheme Implementation Agreement. The AUD$3.8 million (approximately CAD$3.57 million) secured bridge loan (the "Bridge Loan") previously advanced by PharmaCielo to Creso Pharma on June 6, 2019, will now mature on November 30, 2019. The Bridge Loan, which bears interest at a rate of 15% per annum, is secured by a general security agreement over the assets of Creso Pharma and a pledge of the shares of Mernova Medicinal Inc., a subsidiary of Creso Pharma, in favour of PharmaCielo.

"While we are disappointed by this outcome, we have appreciated the interactions between our teams over the past several months and wish them much success in their future endeavours," said David Attard, Chief Executive Officer of PharmaCielo. "Our team has made significant strides over the past several months on an organic basis, expanding cultivation and production with a best in class cost structure, as well as growing international sales. As we near completion of Phase I of our processing centre, which will be capable of producing over 24 metric tonnes of refined cannabis oil capacity per year, we are ramping up sales efforts. We are well-positioned to grow our business and the progress made over the past several months has set the Company up for a strong close to 2019 and solid growth in 2020."

Halted.....

Sector-wide - Up 20 % off the low(s)



Next day :

Down 13 percent today....

Do people realize there is an intrinsic cost of producing CBD isolate, independent of the low low cost of growing CBD hemp?

Even with Colombia’s very low cost of doing anything, growing CBD hemp on a very small scale in greenhouses, I fail to see how that could compete with the insane glut of high CBD hemp in North America at the moment.

https://hempindustrydaily.com/why-harvesting-and-processing-may-be-expensive-lessons-for-this-years-new-hemp-farmers/

PCLO was always a house of cards imo. The current share price + these somewhat nonsensical PRs about “proprietary” extraction methods (CO2 is the least efficient for large scale by the way) support this.

What’s up man, didn’t renew my subscription for iHub, can’t respond to your pm but yeah did a quick scalp on PCLO and the other one...RIP lol. Hope you are killing it!

TORONTO and RIONEGRO, Colombia, Aug. 1, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., is ramping up its oil processing capabilities in the Company's Rionegro, Colombia facility following the recent acquisition and installation of additional high-performance, high-volume extractors, combined with proprietary extraction techniques.

After receiving approval for commercial export of non-psychoactive (CBD) isolate PharmaCielo has expanded its extraction processing capacity to 265 tonnes of dried flower to meet anticipated global demand for its high-grade medicinal cannabis oils, feeding international supply channels and product production lines following the recent achievement of Colombian government approval for commercial export of non-psychoactive (CBD) isolate combined with announcement of the Company's intent to acquire Creso Pharma Limited (ASX:CPH) ("Creso Pharma").

"As global demand for medicinal cannabis oils and extracts continues to outpace supply, we are taking the right steps with prudent investment in processing infrastructure to ensure that we capitalize on business opportunities to become the leading supplier globally," said David Attard, CEO at PharmaCielo. "With the recently announced agreement to acquire Creso Pharma, we have the opportunity to expand our global footprint and add an extensive portfolio of animal and human CBD products, which when combined with commercial export approval and inbound order demand puts us at the stage where we need to ramp up production."

Along with the expansion of its extraction capabilities, PharmaCielo also announced it has surpassed the 18-tonne mark of dried flower currently under inventory and immediately ready for processing. The Company also continues to expand the land area under active cultivation, currently at 12.1 hectares (capable in annual cultivation in excess of 0.48 million kg) from 5.3 hectares at the beginning of the year, with additional cultivation expansion expected to continue throughout the balance of the year.

"Since receiving Colombia's first-issued manufacturing and cultivation licenses, we have utilized the opportunity to conduct trials with the full range of processing equipment and to determine which methodology best meets individual strain and finished-product requirements, as well as to develop proprietary methodologies," added Attard. "Deep experience with all the processing technologies leaves us well positioned to immediately capitalize on installation of the new equipment and not lose valuable production time learning relative ins-and-outs."

The additional processing equipment now in place complements technologies previously manufactured and installed by Canadian firm Vitalis, the global leader in industrial-scale supercritical CO2 extraction, and will immediately increase annual dried flower processing capacity in support of previously announced strategies for the expansion of hectares under cultivation, with a corresponding increase in finished oil production. Laboratory analysis conducted has demonstrated purity of CBD isolate extraction certified as greater than 99+%, and readily accommodating multiple international requirements for commercial import.

Looks like the bottom has been found.....looking to re-enter for a swing.

Well, she's certainly a winner alright !.....



http://ih.advfn.com/stock-market/TSXV/PCLO/stock-news/80408594/pharmacielo-completes-acquisition-of-ubiquo-teleme

Whew !.....man.....Dodged a bullet there !

http://ih.advfn.com/stock-market/TSXV/PCLO/stock-news/80183714/pharmacielo-announces-trading-on-the-otc-market

https://www.fool.ca/2019/06/23/holdanniesunwant-to-cash-in-on-the-marijuana-boom-my-top-cannabis-stock-to-buy-in-june/

Three days later - Whump !.....Nice !




Three days later - Whump !.....Nice !
Useless piece of huh ?......What ?




Useless piece of......Yep !




My goodness !

A fresh batch of ruler-lines.....Oh joy - What could be better ?

nw2019

F.Y.I. https://www.barrons.com/articles/colombia-marijuana-production-51559321831

Yeah but your a big wheel NW!
Yeah I read the news release and there was nothing to like or get excited about anyways. Seen the loss $0.08. Nothing to see here till the end of the year...maybe.

12 hectares under cultivation - That's TINY (= 30 acres)

The property I'm currently living on is 16 acres
The one before this was one was 8
And the one before that was 62

So I've got a pretty good feel for the size of their "field".

And 30 acres is about the size of a small hayfield.

How much of that is "greenhouse" too......I dunno.


Loss of .08 cents on the quarter.....hmmmmm



"Working towards first commercial sales in the 2nd half of 2019 "

And so what's their market cap again ?


Hoo - boy !.....Anyways thanks for the update




PS : OTH - On the other hand - What's this ? https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149029105

PharmaCielo Announces its Financial Results for the First Quarter 2019
PharmaCielo Ltd. (CNW Group/PharmaCielo Ltd.)
NEWS PROVIDED BY
PharmaCielo Ltd.
May 27, 2019, 07:00 ET
Well capitalized with a cash and cash equivalents balance of $40.8 million as of March 31, 2019
Working towards first commercial sales in the 2nd half of 2019
Area under cultivation has grown to ~12 hectares from ~10 hectares at the end of 2018, a 20% increase in area under cultivation
Construction of Colombian processing facility progressing toward production in late Q2/early Q3
Currently in active negotiations in multiple markets in South America and the EU
All figures are in CDN dollars unless otherwise specified

TORONTO and RIONEGRO, Colombia, May 27, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., today announced its financial results for the first quarter ended March 31, 2019.

"PharmaCielo has made significant progress over the past six months toward its objective of generating commercial sales during the second half of 2019," said David Attard, Chief Executive Officer, PharmaCielo Ltd. "The team has achieved the milestones it has targeted – significantly increasing cultivation, expanding oil production capacity, establishing the national cultivar's largest licensed strain portfolio, growing the distribution network, entering JV's in two markets, bolstering R&D with appointment of a top-tier scientific and medical advisory board and receiving the coveted ISO9001 quality assurance certification."

"2019 will continue to be an exciting year for the Company as we focus on completing and producing out of our new oil production facility, generating initial sales and growing sales channels. We are well-capitalized to achieve our objectives and expect to see sales significantly expand into 2020, driven by value-add product development and activation of our international and Colombian sales channels," added Attard.

Financial Highlights – Q1 – 2019
Operating Results
All comparisons below are to the quarter ended March 31, 2018, unless otherwise noted

Total operating expenses of $4.8 million as compared to $9.6 million
Net loss of $7.7 million as compared to $10.0 million
Balance Sheet
All comparisons below are to December 31, 2018, unless otherwise noted

Cash and cash equivalents of $40.8 million as compared to $45.7 million
Total assets of $64.6 million as compared to $66.3 million
Total liabilities of $3.6 million as compared to $3.0 million
Discussion of Operations
The Company's net loss totaled $7.7 million for the three-months ended March 31, 2019 (compared to $10.0 million for the three-months ended March 31, 2018), with a basic loss per common share of $0.08 for the three-months ended March 31, 2019 versus a basic loss per common share of $0.13 for the three-months ended March 31, 2018.

This net loss was primarily due to reverse takeover listing expense of $2.4 million for the three-months ended March 31, 2019 (compared to $Nil in the three-months ended March 31, 2018), common share-based expense of $1.4 million for the three-months ended March 31, 2019 (compared to $7.6 million in the three-months ended March 31, 2018), Salaries and wages $850,403 for the three-months ended March 31, 2019 (compared to $172,063 in the three-months ended March 31, 2018), and Agricultural pre-operational costs of $906,225 for the three-months ended March 31, 2019 (compared to $331,766 in the three-months ended March 31, 2018).

Other expenses were principally due to operating expenses to continue the construction of the Research Technology and Processing Centre.

About PharmaCielo

PharmaCielo Ltd. (TSXV:PCLO) is a global company, headquartered in Canada, with a focus on ethical and sustainable processing and supplying of all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo's principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its nursery and propagation centre located in Rionegro, Colombia.

The boards of directors and executive teams of both PharmaCielo and PharmaCielo Colombia Holdings are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia's ideal location will play in building a sustainable business in the medical cannabis industry, and the Company, together with its directors and executives, is executing on a business plan focused on supplying the international marketplace.

Time to update their chart here maybe....




Today they were up 4.6 % but I'm sensing that that Red Oval is the likely near-term outcome

Mexico legalization very soon! Investors' buying window is now

https://www.marijuanamoment.net/mexican-lawmakers-plan-to-tackle-marijuana-legalization-this-summer/

Definition of "screwed"




Millions of others like ourselves.....Don't trust the governments or Wall Street or nuthin'


LoL - ha-ha-ha - No I don't Tweet - Have never even yet owned a cell phone


https://en.wikipedia.org/wiki/Technophobia



Techno AND Investophobic !

Ok I will check him out occasionally when he’s covering a ticker I’m interested in but I skip through the video until I see my ticker covered. I like to see different perspectives on particular stocks good and bad. Otherwise the video is toooo long my attention span isn’t. He’s always stated that’s his biggest holding and he went all in when it dropped to $1.00 then it dropped a bit. Seen it on twitter. You have a handle on Twitter?
I agree I’m 80% cash right now waiting for summer bargains.

You used to "follow" Tom ?.....That's interesting....
And you say that he's always been a big fan of 48 ?

Ahhh.....Well I guess I maybe ought'a look into that, since, yeah that vid was super-bullish.

No I'm not IN 'em but - he DID make 'em sound good !


So HARD to get long at this (late?) stage in the market's cycle !



Feels a LOT like playing musical chairs with only a few chairs remaining.


Or maybe like playing some "Russian" Roulette with a couple of bullets in the chamber.

PharmaCielo Announces its Financial Results for the Fourth Quarter and Fiscal Year 2018
PharmaCielo Ltd. (CNW Group/PharmaCielo Ltd.)
NEWS PROVIDED BY
PharmaCielo Ltd.
Apr 18, 2019, 07:50 ET
PharmaCielo expects to begin commercial sales in 2019.
Oil processing facility is on track for commercial operation and GMP certification during Q3-2019, enabling large-scale production and sale of refined cannabis oil.
Currently, 10 hectares are under active cultivation, expanding to 20 hectares (~2.15 million square feet) by year-end 2019, backed by 20 proprietary registered strains and 186 strains in the Company's germplasm bank.
PharmaCielo's common shares began trading on the TSX Venture Exchange ("TSXV" or "TSX Venture") under the ticker PCLO on January 18, 2019.
Well capitalized with a cash balance of US$33.5 million as of December 31, 2018.
All figures are in U.S. dollars unless otherwise specified

TORONTO and RIONEGRO, Colombia, April 18, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announces its financial results for the fourth quarter and full year ended December 31, 2018.

PharmaCielo Ltd. CEO David Attard commented on the company's continuing progress. "2018 was a year of incredible growth, culminating in the public listing of our common shares in January 2019. We are expanding our cultivation and processing operations to begin commercial sales of refined cannabis oil in 2019, having already received more inbound requests for product than we are able to fulfill in the near term. We are ready to sell, with sales licensing and ISO 9001 certification in place and an initial 20 proprietary strains registered for commercial production. We anticipate the completion of our first major processing expansion in Q2 and our GMP certification in Q3."

"PharmaCielo has been structured with a singular strategic objective in mind – to be a dominant global supplier of both branded and white-labelled refined cannabis oil for large global distribution channels. We have the product consistency and quality, reliability of supply and structural cost advantage that will enable us to provide the customized extracts that the global market is looking for, making us very well positioned to become a dominant global cannabis oil supplier," said Dr. Delon Human, PharmaCielo's Global Head of Health and Innovation. "We have recently expanded our Medical and Scientific Advisory Board, adding a group of top global medical researchers and scientists, to enhance our product development strategy and quickly bring high-quality, customized products to market. Our team has decades of collective experience both selling into these channels and running the very global enterprises currently expressing increased interest and demand."

Developments Subsequent to the end of fiscal 2018

For a more comprehensive overview of these recent developments, please refer to the corresponding press releases on the Company's website (www.pharmacielo.com) and the Company's press releases and other regulatory filings on SEDAR (www.sedar.com).

On April 9, 2019, PharmaCielo appointed a Medical and Scientific Advisory Board composed of an international panel of renowned physicians, researchers, veterinarians, engineers and academics. This advisory board will guide PharmaCielo's research and development of special cannabinoids-based formulations and derived products with therapeutic properties.
On March 29, 2019, PharmaCielo announced that its Colombian subsidiary had received approval from the national cultivar registry for the listing of 10 proprietary cannabis strains. This brings the number of approved strains held by PharmaCielo to 20, following the Company's February 6, 2019 announcement of the approval of an initial 10 strains. PharmaCielo is the largest holder of approved strains in Colombia.
On March 19,2019, PharmaCielo received ISO 9001 Quality Assurance Certification for its medicinal cannabis cultivation and processing operations in Colombia.
On January 28, 2019, PharmaCielo announced that it had established an equity joint venture with Mino Labs S.A. de C.V, a specialty pharmaceutical company and medical supply distributor based in Mexico, to bring medicinal cannabis oil to Mexico.
On January 18, 2019, PharmaCielo began trading on the TSX Venture Exchange under the ticker PCLO.
On January 15, 2019, the Company completed an RTO with AAJ Capital 1 Corp. ("AAJ").
Discussion of Operations

The Company's net loss totaled $24.4 million for the twelve-month year ending December 31, 2018 (compared to $5.4 million for the five-month period ending December 31, 2017; and compared to $7.6 million for the twelve-month year ending July 31, 2017), with a basic loss per share of $0.31 for the twelve-month year ending December 31, 2018 versus a basic loss per share of $0.07 for the five-month period ending December 31, 2017, and a basic loss per share of $0.12 for the twelve-month year ending July 31, 2017.

This net loss was primarily due to a share-based payments of $14.4 million for the twelve-month year ended December 31, 2018 (compared to $111,256 in the five-month period ending December 31, 2017, and $2.3 million in the twelve-month year ending July 31, 2017). These share-based expenses were incurred primarily for options granted to employees and directors who had worked for and developed the Company over the years.

Other expenses were principally due to operating expenses to continue the construction of the Research Technology and Processing Centre, and to grow and harvest the plants. Additionally, operating expenses were incurred in Canada for legal, travel, and other fees incurred in order to facilitate the capital raise to complete the Plan of Arrangement. The one-time non-cash item for options was the largest expense.

PharmaCielo Grants Restricted Share Units

Effective April 17, 2019 the Company has granted Restricted Share Units ("RSUs") as follows (i) 20,000 RSUs to Doug Bache, a director of the Company; half of which vest six months from the grant date and half of which vest one year from the grant date; (ii) 75,000 RSUs to Carlos Manuel Uribe, a director of the Company; half of which vest six months from the grant date and half of which vest one year from the grant date; and (iii) 913,000 RSUs to employees and consultants of the Company; half of which vest one year from the grant date and half of which two years from the grant date. Each RSU entitles the holder thereof to receive one common share of the Company (each, a "Common Share").

The RSU's are governed by the RSU plan of the Company (the "RSU Plan"). The RSU Plan was approved by shareholders of the Company on September 20, 2019. The number of Common Shares that may be reserved for issuance pursuant to awards granted under the RSU Plan is 3,101,435 Common Shares, representing 3.3% of the 93,976,962 Common Shares that were issued and outstanding when the Company completed its qualifying transaction (the "Qualifying Transaction") pursuant to the policies of the TSXV and together with the number of Common Shares issuable under the stock option plan of the Company and the deferred share unit plan of the Company may be up to 18,795,392 Common Shares, being 20% of 93,976,962 issued and outstanding Common Shares when the Company completed its Qualifying Transaction. After this issuance there are 1,008,000 RSUs outstanding.

About PharmaCielo

PharmaCielo Ltd. (TSXV: PCLO) is a global company, headquartered in Canada, with a focus on ethical and sustainable processing and supplying of all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo's principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its nursery and propagation centre located in Rionegro, Colombia.

The boards of directors and executive teams of both PharmaCielo and PharmaCielo Colombia Holdings are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia's ideal location will play in building a sustainable business in the medical cannabis industry, and the Company, together with its directors and executives, is executing on a business plan focused on supplying the international marketplace.

Yeah this one been a slow bleed with no end in sight.
I used to watch Tom, he loves his true north. You in that one?

PCLO LoL

re: Canada's Outdoor Grow ambitions :
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148300711

“We expect to be competitive with those overseas jurisdictions that claim to be able to produce for less than 20 cents a gram,” Mr. Merker said, referring to the company’s estimated cash cost of production of dried product that does not including packaging.

https://outline.com/sD6yzj

Wowza, just took a look at this one...kinda forgot about it. Apparently this one is still over valued but the market isn’t helping any weed stocks today the index is red MARIJUANA INDEX
NORTH AMERICAN INDEX UNITED STATES INDEX CANADIAN INDEX
296.72 -8.50

Doubt creeps in.....

Whew - Dodged a bullet there -

Thought that 9 MIGHT hold up but can see that it hasn't

Why - It's even hit 8.42 here now (TANKED whilst I was composing)

Maybe it'll even hit my Oval TODAY !....LoL

Thanks for the explanation...

As for BBM though ?....Gosh well - I'm just not too sure :

Although, granted it's the markets' perception which matters !

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147759896


At least he (no doubt) speaks Spanish well !

On the hourly it had a big bounce off the $9.20 area previously...doesn’t mean it will again but watching along with so many others. That bbm is a beauty, nice call!!

Come to Papa Darlin' ..... Wo !

Holy freaking Deuce !





Oh !.....Uh......Ummmm......Ok ;




Now what ? . . . . . (9.56)





Oh yeah - Hey - Why 9.20 ?

Thanks - Good to hear

Khiron / Pharma / Blueberries





Overhead "trendline" on PCLO ?

I think that’s pretty accurate, I’ve got $9.20 as the bounce point.

Wild guess pullback

Dang - Yeah/no eh ?....Have a nice weekend !

This rat bastard gonna give me grey hair lol only 3% now?! Miller time!